Journal Article

Magic but treatable? Tumours due to loss of Merlin

C. O. Hanemann

in Brain

Published on behalf of The Guarantors of Brain

Volume 131, issue 3, pages 606-615
Published in print March 2008 | ISSN: 0006-8950
Published online October 2007 | e-ISSN: 1460-2156 | DOI:

Show Summary Details


Alterations in the NF2 gene coding for merlin cause all tumours that occur in patients suffering from neurofibromatosis type 2, all spontaneous schwannomas and the majority of meningiomas. Thus merlin's tumours are quite frequent and also numerous when inherited as part of meurofibromatosis type 2. Tumours caused by mutations in the NF2 gene are benign and thus do not respond to classical chemotherapy. Surgery and radiosurgery are only local therapies and the patients frequently require multiple treatments. This highlights the medical need to understand how merlin loss results in tumourigenesis and the need to find new systemic therapies. The benign, and therefore genetically stable and homogenous character of the tumours allows establishment of meaningful tumour models. This brings about the rather unique opportunity to both analyse the consequences of the gene defect and identify new therapeutic targets. In this review, I will first describe the phenotypes associated with ‘merlin’ mutations and consider differential diagnosis, in particular Schwannomatosis, for which a gene defect has been described recently. Existing therapeutic options, surgery and radiosurgery, including new data on the latter will be reviewed. Finally, I will discuss how loss of merlin leads to tumourigenesis in order to understand the rationale for emerging new therapeutic targets.

Keywords: schwannoma; meningioma; ependymoma; neurofibromatosis 2; merlin

Journal Article.  7252 words.  Illustrated.

Subjects: Neurology ; Neuroscience

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.